Heptocellular Carcinoma (HCC) is a "silent killer". It develops unseen, often only to be found when it’s too late to save patients. It is already the third leading cause of cancer death,1 and the global incidence of HCC is increasing, especially in developed countries.2
But it doesn’t have to be that way. We refuse to let it continue as a "silent killer". We’re turning up the volume on HCC.
Healthcare is rapidly shifting, towards more personalised care that’s more in tune with patients, embracing digital technologies that enable new possibilities. At Roche, we are shaping a new class of diagnostic algorithms.
Introducing the Elecsys® GAAD in-vitro diagnostic multivariate index assay. It will be the only IVD-approved algorithm to help you diagnose early stage HCC and save lives. Combining Elecsys® AFP and Elecsys® PIVKA-II assay results, along with gender and age, Elecsys® GAAD communicates patients’ risk factor clearly, so you may be able to evaluate earlier and save more lives.
It’s simple and intuitive to use, and can be adapted to your current workflow, so there will be no disruption to you.